Dr Cortés, Head of Breast Cancer and Gynaecological Tumours at the Ramón y Cajal University Hospital in Madrid, Spain, provides his expert insight into key data presented at ASCO 2018 and what they may mean for optimizing clinical outcomes for patients with advanced breast cancer.
Key topics include:
The place of CDK4/6 inhibitors in relation to endocrine therapy in the treatment sequence for HR+/HER2- advanced breast cancer.
Whether the differing safety profiles of CDK4/6 inhibitors are important when making decisions regarding patient management.
The current challenges for conserving the quality of life of patients with HR+/HER2- advanced breast cancer, compared with managing disease progression.
Whether a broader choice of treatment options may be available in the near future for advanced breast cancer based on the wealth of early phase studies presented at ASCO 2018.
Specific data for advanced breast cancer that were of particular interest for Dr Cortés at ASCO 2018, and any implications of these for the management of patients from a national and regional perspective in Spain.
Clinical Expert Video Series
Watch internationally renowned breast cancer clinicians discussing the latest data from the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5, and what they may mean for clinical practice.
Javier Cortés received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996. He continued his studies at the University of Navarra, specializing in Medical Oncology at the Clínica Universitaria de Navarra, where he continued as Assistant in the Department of Oncology from 2002. He was Associate Professor of Oncology in the Faculty of Medicine at the University of Navarra during that period. Dr Cortés was awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. From June 2003 to July 2015, he worked in the Department of Medical Oncology at the Hospital Vall d’Hebron, Barcelona, where he was Coordinator of the Teaching and Training Programme for Residents in Oncology and Senior Specialist in breast cancer with a special interest in new drugs development. Dr Cortés was the Head of the Breast Cancer Program and the Melanoma Unit from July 2006 to August 2015. From September 2015, he has been Head of the Breast Cancer and Gynaecological Tumours at Ramon y Cajal University Hospital in Madrid, Clinical Investigator of the Breast Cancer Research Program at Vall d’Hebron Institute of Oncology, and Head of the Breast Cancer Program, IOB Institute of Oncology, Madrid and Barcelona, Spain.
In addition to his medical specialties, he has two master’s degrees in “Medical Direction and Clinical Management” by the Universidad Nacional de Educación a Distancia (UNED) and “Research Methodology in Health Sciences” by the Universidad Autonoma de Barcelona and a degree in “Statistics in Health Sciences” by the Universidad Autonoma de Barcelona.
Dr Cortés is the author of more than 200 publications, especially regarding breast tumours and new drugs and has made more than 500 communications at different conferences. He actively participates in the development of numerous national and international clinical investigations, especially in relation to drugs directed against molecular targets and new chemotherapy agents, and he is an ad hoc reviewer of various oncology journals.
Dr Cortés is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO), American Association for Cancer research (AACR) and a member of the Scientific Committee of the European Society of Medical Oncology.
Disclosures: Honoraria from Roche, Novartis, Eisai, Celgene and Pfizer. Consulting/advisor for Roche, Celgene, AztraZeneca, Cellestia Biotech, Biothera and Merus.
ASCO 2018 Highlights